3 Things About Regeneron That Smart Investors Know

As COVID-19 hospitalizations soared last year and the world waited for news about vaccines, it seemed as though the news included daily updates on potential treatments. A lot of options were considered, among them the investigative monoclonal antibody cocktail from Regeneron Pharmaceuticals (NASDAQ: REGN).

After then-President Trump contracted COVID-19, he gave the REGN-COV antibody cocktail some credit for his recovery. Unlike some other, over-hyped alternatives, Regeneron's offering was shown to be effective in well-designed clinical studies.

The Trump administration pushed for the treatment to receive an Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) and made it available to U.S. COVID-19 patients for free. That support resulted in $3.15 billion worth of orders for 1.5 million doses at $2,100 each.

Source Fool.com